AbbVie (ABBV) Declares $0.42 Quarterly Dividend; 2.8% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
FDA Votes to Revise Current Indications for Testosterone Therapy
September 17, 2014 4:35 PM EDTAn FDA advisory panel voted 20-1 to revise approved indications for prescribing testosterone therapies.
Stocks on watch include Repros Therapeutics (NASDAQ: RPRX), Auxilium Pharma (NASDAQ: AUXL), Endo Int'l (NASDAQ: ENDP), Lipocine (NASDAQ: LPCN), AbbVie (NYSE: ABBV), and Lilly & Co. (NYSE: LLY).
